News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Giuseppe Banna: Promising results for Telisotuzumab Vedotin in advanced NSCLC
Aug 27, 2024, 22:06

Giuseppe Banna: Promising results for Telisotuzumab Vedotin in advanced NSCLC

Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on X:

“The Phase II LUMINOSITY trial shows promising results for Telisotuzumab Vedotin in treating c-Met protein–overexpressing advanced NSCLC, especially in patients with high c-Met expression.”

Giuseppe Banna

Source: Giuseppe Banna/X

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

Authors: D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Goldman, Fedor Moiseenko, Elena Filippova, Irfan Cicin, Tudor Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope Bradbury, Mor Moskovitz, Nuran Katgi, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji-Youn Han, Shang-Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih-Hsi Kuo, Kazumi Nishino, Se-Hoon Lee, David Planchard, Christina Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, and Shun Lu.

Giuseppe Banna

Aaron S. Mansfield Alona Zer c-Met protein cancer Chih-Hsi Kuo Christina Baik Christine Ratajczak Chunling Liu D. Ross Camidge David Planchard Elena Filippova Ellen Bolotin Fedor Moiseenko Giuseppe Banna Hidehito Horinouchi Irfan Cicin Jair Bar Ji-Youn Han Jim Looman Jonathan Goldman Kazumi Nishino Kristof Cuppens LUMINOSITY trial Martha Li Mor Moskovitz Nathalie Daaboul Nicolas Girard NSCLC Nuran Katgi OncoDaily Oncology Pascale Tomasini Penelope Bradbury Peter Ansell Se-Hoon Lee Shang-Yin Wu Shobhit Baijal Shun Lu Summer Xia Telisotuzumab Vedotin Tudor Ciuleanu
Special Coverage
Blog
Nov 21, 2024, 06:52
Sylvester’s third annual Art is Medicine exhibit's new theme is "The Bridge to Bahia"
Blog
Nov 21, 2024, 06:49
OncoInfluencers to Follow on Social Media: Dr. Melvin L.K. Chua
Blog
Nov 21, 2024, 06:44
Hedley Lewis: Gratitude to all The Cows who participated in the Virgin Active South Africa Ride Joburg
Insight
Nov 21, 2024, 06:29
Sami Mansfield: What if improving metabolic health could reduce cancer risks and improve outcomes?
Blog
Nov 21, 2024, 06:27
Julie Gralow: Comprehensive Genomic Profiling Improves Precision Therapy Use And Patient Survival
Insight
Nov 20, 2024, 20:44
Baris Turkbey: Excited to announce NCI Molecular Imaging members presenting their research at RSNA2024
Blog
Nov 20, 2024, 20:38
Franklin Iheanacho: Changing treatment patterns for hepatocellular carcinoma
Insight
Nov 20, 2024, 20:27
HIPEC improves overall survival in recurrent epithelial ovarian cancer
Blog
Nov 20, 2024, 19:12
Medicaid Cancer Foundation at 1Ummah Annual Convention
Insight
Nov 20, 2024, 19:12
Sahar Mansour: Advancing Breast Microcalcification Detection with AI
Blog
Nov 20, 2024, 19:12
Reflecting on Progress and Partnerships in Lung Cancer Care – Sarah Cannon Research Institute
Blog
Nov 20, 2024, 19:12
Virtual tumor board on the management of a patient with Metastatic Squamous NSCLC - IASLC